The 36-month beta value for VTGN is at 0.76. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VTGN is 24.29M, and currently, shorts hold a 5.49% of that float. The average trading volume for VTGN on April 01, 2024 was 272.93K shares.
VTGN) stock’s latest price update
VistaGen Therapeutics Inc (NASDAQ: VTGN) has experienced a rise in its stock price by 15.54 compared to its previous closing price of 4.57. However, the company has seen a gain of 25.27% in its stock price over the last five trading days. InvestorPlace reported 2024-03-31 that Finding undiscovered opportunities can result in significant profits in an investment landscape frequently controlled by well-known giants. These three obscure stocks have the potential to provide impressive profits.
VTGN’s Market Performance
VistaGen Therapeutics Inc (VTGN) has experienced a 25.27% rise in stock performance for the past week, with a 1.34% rise in the past month, and a 2.72% rise in the past quarter. The volatility ratio for the week is 9.28%, and the volatility levels for the past 30 days are at 6.63% for VTGN. The simple moving average for the past 20 days is 21.67% for VTGN’s stock, with a 26.78% simple moving average for the past 200 days.
Analysts’ Opinion of VTGN
Many brokerage firms have already submitted their reports for VTGN stocks, with Jefferies repeating the rating for VTGN by listing it as a “Buy.” The predicted price for VTGN in the upcoming period, according to Jefferies is $15 based on the research report published on December 07, 2023 of the previous year 2023.
Maxim Group, on the other hand, stated in their research note that they expect to see VTGN reach a price target of $30. The rating they have provided for VTGN stocks is “Buy” according to the report published on August 07th, 2023.
VTGN Trading at 12.29% from the 50-Day Moving Average
After a stumble in the market that brought VTGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.63% of loss for the given period.
Volatility was left at 6.63%, however, over the last 30 days, the volatility rate increased by 9.28%, as shares surge +3.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.42% upper at present.
During the last 5 trading sessions, VTGN rose by +25.27%, which changed the moving average for the period of 200-days by +117.28% in comparison to the 20-day moving average, which settled at $4.35. In addition, VistaGen Therapeutics Inc saw 2.72% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTGN starting from COMMODORE CAPITAL LP, who purchase 775,756 shares at the price of $23.15 back on Aug 07 ’23. After this action, COMMODORE CAPITAL LP now owns 1,575,000 shares of VistaGen Therapeutics Inc, valued at $17,961,079 using the latest closing price.
Stock Fundamentals for VTGN
Current profitability levels for the company are sitting at:
- -32.53 for the present operating margin
- 0.25 for the gross margin
The net margin for VistaGen Therapeutics Inc stands at -30.77. The total capital return value is set at -0.27. Equity return is now at value -44.55, with -39.89 for asset returns.
Based on VistaGen Therapeutics Inc (VTGN), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -11.57. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -3766.79.
Currently, EBITDA for the company is -58.68 million with net debt to EBITDA at 3.75. When we switch over and look at the enterprise to sales, we see a ratio of 17.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.75.
Conclusion
In conclusion, VistaGen Therapeutics Inc (VTGN) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
